AstraZeneca (NASDAQ:AZN) has obtained FDA approval for its drug Voydeya, also called danicopan, as an add-on remedy to Ultomiris or Soliris within the remedy of extravascular hemolysis in adults with the uncommon blood dysfunction paroxysmal nocturnal hemoglobinuria, or PNH.
AstraZeneca mentioned Voydeya was developed as an add-on treatment to its PNH medication Ultomiris or Soliris for the roughly 10% to twenty% of sufferers who expertise clinically important extravascular hemolysis whereas handled with a C5 inhibitor.
Voydeya was permitted by Japanese regulators in January and has been advisable for approval within the EU, AstraZeneca mentioned.